Articles by Alicia Ault

James C. Foster, CEO of Charles River Laboratories, celebrated the company's five years of public trading by ringing the closing bell at the New York Stock Exchange on June 13.

When Novartis International announced in February that it was making a play for two generic drug companies, it was viewed as an acknowledgment that generics could play an increasingly important role in the pharmaceutical business.

A National Academies committee issued a report in May that calls for the creation of a new category of visa to make it easier for international graduate students and postdocs to study in the United States.

National Academies report calls for a new visa category for international grads and postdocs

More that three years after Sept. 11, 2001, researchers and scholars who wish to come to America to study, conduct research, or attend scientific meetings are still feeling the reverberations of that day.

Embryonic stem cell research is proceeding apace in many nations but continues to face political and economic hurdles in the United States, despite California voters' approval of a $3 billion war chest for stem cell research conducted in that state.

Courtesy of Mark SewardCombinatorial chemistry and high-throughput screening have been the rage in drug discovery since the late 1990s, but plant and animal sources still hold promise. In particular, venoms have proven to be rich areas for exploitation. Drugs derived from snakes, vampire bats, and Gila monsters are all nearing regulatory review and potentially, approval. But in September, a Food and Drug Administration advisory panel voted against approval of AstraZeneca's Exanta, a cobra venom-

Senators skip meeting on potential ways to improve $5.6 billion US biodefense program

US Congressional subcommittee holds hearing on clinical trial disclosure rules